Anticancer Research 1992-01-01

Effect of hypoxia and acidosis on the cytotoxicity of mitoxantrone, bisantrene and amsacrine and their platinum complexes at normal and hyperthermic temperatures.

T S Herman, B A Teicher, A Varshney, V Khandekar, T Brann

Index: Anticancer Res. 12(3) , 827-36, (1992)

Full Text: HTML

Abstract

In an effort to synthesize drugs which would become much more cytotoxic at clinically achievable hyperthermic temperatures, complexes of the tetrachloro-platinum(II) dianion were made with two anthracene dye derivatives, MITOX and BISANT, and the acridine dye derivative m-AMSA. As compared with the parent drug, PtCl4(MITOX)2 was less cytotoxic at 37 degrees C and more cytotoxic at 42 degrees C and 43 degrees C especially at pH 6.45. In contrast, the PtCl4(BISANT)2 was more cytotoxic than BISANT under all conditions. M-AMSA was again shown to be less cytotoxic at elevated temperatures but PtCl4(m-AMSA)2 was more cytotoxic especially at 43 degrees C and pH 6.45. Platinum levels in cells treated for 1 hr with 25 microM at 37 degrees C, 42 degrees C and at pH 7.40 versus pH 6.45 demonstrated no significant differences depending on temperature or pH except for PtCl4(MITOX)2 where approximately 4 times higher intracellular platinum levels were present at pH 6.45 versus pH 7.40, although this finding did not correlate with cytotoxicity. These results suggest that PtCl4(MITOX)2 and PtCl4(m-AMSA)2 may be highly interactive drugs with local hyperthermia.


Related Compounds

  • Bisantrene

Related Articles:

In vitro effects of bisantrene on fresh clonogenic leukemia cells: a preliminary study on 15 cases.

1990-01-01

[Haematologica 75(6) , 527-31, (1990)]

Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.

1991-01-01

[Med. Pediatr. Oncol. 19(2) , 126-8, (1991)]

Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity.

2014-04-29

[Clin. Cancer Res. 2(6) , 973-80, (1996)]

Synthesis, DNA-damaging and cytotoxic properties of novel topoisomerase II-directed bisantrene analogues.

1998-01-20

[Bioorg. Med. Chem. Lett. 8(2) , 121-6, (1998)]

Bisantrene in advanced, hormone-resistant carcinoma of the prostate: an Illinois Cancer Council phase II study.

1990-08-01

[Invest. New Drugs 8(3) , 313-5, (1990)]

More Articles...